Molecular Characteristics of Fibrolamellar Hepatocellular Carcinoma

详细信息    查看全文

• 作者：Attila Patonai (1)
  Boglárka Erdélyi-Belle (1)
  Anna Korompay (1)
  áron Somorácz (1)
  Péter T?rzs?k (1)
  Ilona Kovalszky (2)
  Tamás Barbai (1)
  Erzsébet Rásó (1)
  Gábor Lotz (1)
  Zsuzsa Schaff (1)
  András Kiss (1)
  
• 关键词：Fibrolamellar hepatocellular carcinoma ; Hepatocellular carcinoma ; Cholangiocellular carcinoma ; Epidermal growth factor receptor ; K ; RAS mutation
• 刊名：Pathology & Oncology Research
• 出版年：2013
• 出版时间：January 2013
• 年：2013
• 卷：19
• 期：1
• 页码：63-70
• 全文大小：713KB
• 参考文献：1. Abdul-Al HM, Wang G, Makhlouf HR, Goodman ZD (2010) Fibrolamellar hepatocellular carcinoma: An immunohistochemical comparison with conventional hepatocellular carcinoma. Int J Surg Pathol 18:313-18
  2. Kannangai R, Vivekanandan P, Martinez-Murillo F, Choti M, Torbenson M (2007) Fibrolamellar carcinomas show overexpression of genes in the RAS, MAPK, PIK3, and xenobiotic degradation pathways. Hum Pathol 38:639-44 dx.doi.org/10.1016/j.humpath.2006.07.019">CrossRef
  3. Liu S, Chan KW, Wang B, Qiao L (2009) Fibrolamellar hepatocellular carcinoma. Am J Gastroenterol 104:2617-624 dx.doi.org/10.1038/ajg.2009.440">CrossRef
  4. Torbenson M (2007) Review of the clinicopathologic features of fibrolamellar carcinoma. Adv Anat Pathol 14:217-23 dx.doi.org/10.1097/PAP.0b013e3180504913">CrossRef
  5. Ward SC, Huang J, Tickoo SK, Thung SN, Ladanyi M, Klimstra DS (2010) Fibrolamellar carcinoma of the liver exhibits immunohistochemical evidence of both hepatocyte and bile duct differentiation. Mod Pathol 23:1180-190 dx.doi.org/10.1038/modpathol.2010.105">CrossRef
  6. Patonai A, Erdélyi-Belle B, Korompay A, Somorácz á, Straub BK, Schirmacher P, Kovalszky I, Lotz G, Kiss A, Schaff Z (2011) Claudins and tricellulin in fibrolamellar hepatocellular carcinoma. Virchows Arch 458:679-88 dx.doi.org/10.1007/s00428-011-1077-y">CrossRef
  7. Kakar S, Chen X, Ho C, Burgart LJ, Sahai V, Dachrut S, Yabes A, Jain D, Ferrell LD (2009) Chromosomal changes in fibrolamellar hepatocellular carcinoma detected by array comparative genomic hybridization. Hum Pathol 22:134-41
  8. International Consensus Group for Hepatocellular Neoplasia (2009) Pathologic diagnosis of early hepatocellular carcinoma: A report of the International Consensus Group for Hepatocellular Neoplasia. Hepatology 49:658-64 dx.doi.org/10.1002/hep.22709">CrossRef
  9. Libbrecht L, Severi T, Cassiman D, Vander Borght S, Pirenne J, Nevens F, Verslype C, van Pelt J, Roskams T (2006) Glypican-3 expression distinguishes small hepatocellular carcinomas from cirrhosis, dysplastic nodules, and focal nodular hyperplasia-like nodules. Am J Surg Pathol 30:1405-411 dx.doi.org/10.1097/01.pas.0000213323.97294.9a">CrossRef
  10. Sirivatanauksorn Y, Sirivatanauksorn V, Lemoine NR, Williamson BR, Davidson BR (2001) Genomic homogeneity in fibrolamellar carcinomas. Gut 49:82-6 dx.doi.org/10.1136/gut.49.1.82">CrossRef
  11. Vivekanandan P, Torbenson M (2008) Epigenetic insility is rare in fibrolamellar carcinomas but common in viral-associated hepatocellular carcinomas. Mod Pathol 21:670-75 dx.doi.org/10.1038/modpathol.2008.32">CrossRef
  12. Buckley AF, Burgart LJ, Kakar S (2006) Epidermal growth factor receptor expression and gene copy number in fibrolamellar hepatocellular carcinoma. Hum Pathol 37:410-14 dx.doi.org/10.1016/j.humpath.2005.12.009">CrossRef
  13. Llovet JM, Bruix J (2008) Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol 48:S20–S37 dx.doi.org/10.1016/j.jhep.2008.01.022">CrossRef
  14. Ishak KG, Goodman ZD, Stocker JT (2001) Tumors of the Liver and Intrahepatic Bile Ducts. Atlas of Tumor Pathology, Third Series, Fascicle 31. Armed Forces Institute of Pathology, Washington, DC
  15. Ikari A, Atomi K, Takiguchi A, Yamazaki Y, Miwa M, Sugatani J (2009) Epidermal growth factor increases claudin-4 expression mediated by Sp1 elevation in MDCK cells. Biochem Biophys Res Commun 384:306-10 dx.doi.org/10.1016/j.bbrc.2009.04.120">CrossRef
  16. Kojima T, Murata M, Yamamoto T, Lan M, Imamura M, Son S, Takano K, Yamaguchi H, Ito T, Tanaka S, Chiba H, Hirata K, Sawada N (2009) Tight junction proteins and signal transduction pathways in hepatocytes. Histol Histopathol 24:1463-472
  17. Cieply B, Zeng G, Proverbs-Singh T, Geller DA, Monga SPS (2009) Unique phenotype of hepatocellular cancers with exon-3 mutations in beta-catenin gene. Hepatology 49:821-31 dx.doi.org/10.1002/hep.22695">CrossRef
  18. Vivekanandan P, Daniel H, Yeh MM, Torbenson M (2010) Mitochondrial mutations in hepatocellular carcinomas and fibrolamellar carcinomas. Mod Pathol 23:790-98 dx.doi.org/10.1038/modpathol.2010.51">CrossRef
  19. Li W, Tan D, Zenali MJ, Brown RE (2010) Constitutive activation of nuclear factor- kappa B (NF-kB) signaling pathway in fibrolamellar hepatocellular carcinoma. Int J Clin Exp Pathol 3:238-43
  20. Sethi S, Tageja N, Singh J, Arabi H, Dave M, Badheka A, Revankar S (2009) Hyperammonemic encephalopathy: A rare presentation of fibrolamellar hepatocellular carcinoma. Am J Med Sci 338:522-24 dx.doi.org/10.1097/MAJ.0b013e3181bccfb4">CrossRef
  21. Roskams T, De Vos R, Van Damme DG, Desmet V (1998) Heparan sulphate proteoglycan expression in primary liver tumors. J Pathol 185:190-97 dx.doi.org/10.1002/(SICI)1096-9896(199807)185:3<290::AID-PATH91>3.0.CO;2-I">CrossRef
  22. Li H-G, Xie D-R, Shen X-M, Li H-H, Zeng H, Zeng Y-J (2005) Clinicopathological significance of expression of paxilin, syndecan-1 and EMMPRIN in hepatocellular carcinoma. W J Gastroent 11:1445-451
  
• 作者单位：Attila Patonai (1)
  Boglárka Erdélyi-Belle (1)
  Anna Korompay (1)
  áron Somorácz (1)
  Péter T?rzs?k (1)
  Ilona Kovalszky (2)
  Tamás Barbai (1)
  Erzsébet Rásó (1)
  Gábor Lotz (1)
  Zsuzsa Schaff (1)
  András Kiss (1)
  
  1. 2nd Department of Pathology, Semmelweis University Budapest, üll?i út 93, 1091, Budapest, Hungary
  2. First Institute of Pathology and Experimental Cancer Research, Semmelweis University Budapest, Budapest, Hungary
  
• ISSN：1532-2807

文摘

Fibrolamellar hepatocellular carcinoma (FLC) occurs in non-cirrhotic liver and the etiopathogenesis is still obscure. Both hepatocellular and cholangiocellular markers are expressed in the tumor, however, molecular alterations and altered pathways playing role in the tumor pathogenesis are not clearly identified. The purpose of the present study was to compare the expression level of EGFR, syndecan-1 and ?-catenin in FLC, conventional hepatocellular carcinoma (cHCC) and cholangiocellular carcinoma (CCC) and to investigate the possibility of mutation both in EGFR and K-RAS. Eight FLCs were compared with 7 cHCCs, 7 CCCs and 5 normal liver samples. Cytokeratins 7, 8, 18, 19, HepPar1 (HSA), EGFR, syndecan-1 (CD138) and ?-catenin were detected by immunohistochemistry. In addition EGFR, ?-catenin and syndecan-1 were evaluated by digital morphometry and K-RAS, EGFR mutations in FLC cases using paraffin-embedded samples. All FLCs were positive for HepPar1 (HSA) and cytokeratins 7, 8, 18, but negative for cytokeratin 19 by immunohistochemistry. EGFR was significantly overexpressed in all three tumor types, being highest in FLCs (p--,0001). EGFR, K-RAS mutation analyses revealed no mutations in exons studied in FLCs. Our findings proved that expression of EGFR is higher in FLC than in other types of primary malignant hepatic tumors and no K-RAS mutation can be detected, so FLC is a good candidate for anti-EGFR treatment.